Document Detail

The Role of p21 and p53 Proteins in Congenital Cholesteatoma.
MedLine Citation:
PMID:  23324739     Owner:  NLM     Status:  In-Data-Review    
OBJECTIVE: Immunoexpression analysis of p53 and p21 in congenital cholesteatoma with assessing their exact localization in cholesteatoma layers and the level of expression. P53 and p21 are apoptosis-related molecules that regulate cell cycle. These markers have been not completely evaluated in congenital cholesteatoma, and the role of apoptosis in congenital cholesteatoma is also not completely understood.
METHODS: Congenital cholesteatoma samples, a study group (n = 13) and normal auditory meatal skin, a control group (n = 12) from patients who underwent surgery for cholesteatoma were included in the study. Acquired cholesteatoma samples were used as a comparable group (n = 12). Tissue sections were investigated with the immunohistochemistry technique based on binding of biotinylated secondary antibody with the enzyme-labeled streptavidin with using appropriate primary antibodies. Cells with immunoexpression of analyzed antigens: p53 and p21 were defined as antigen positive. In each section, cells were counted, and the percentage of positive cells was determined. The level of significance was set at p < 0.05.
RESULTS: The mean percentage of p21-positive was statistically significant higher in congenital cholesteatoma than in the control group (p < 0.05). There was no meaningful difference between congenital and acquired cholesteatoma with respect to p21 expression. There was significant difference between congenital and acquired cholesteatoma regarding p53.
CONCLUSION: Up-regulation of p21 protein is expected to play a significant role in CC development. Apoptosis is an important process in the pathogenesis of congenital cholesteatoma. It seems reasonable to perform studies on apoptosis in congenital cholesteatoma in the prospective way taking into consideration more specimens.
Ewa Olszewska; Justyna Rutkowska; Amir Minovi; Andrzej Sieskiewicz; Marek Rogowski; Stefan Dazert
Related Documents :
11390449 - Aspirin inhibits in vitro maturation and in vivo immunostimulatory function of murine m...
19401559 - Identification of crassin acetate as a new immunosuppressant triggering heme oxygenase-...
12218119 - Loss of type i ifn receptors and impaired ifn responsiveness during terminal maturation...
9794369 - Antigen-specific t lymphocytes regulate lipopolysaccharide-induced apoptosis of dendrit...
16537609 - A simian virus 5 (sv5) p/v mutant is less cytopathic than wild-type sv5 in human dendri...
15342209 - Interferon-beta enhances monocyte and dendritic cell expression of b7-h1 (pd-l1), a str...
11564829 - Il-10 improves skin disease and modulates endothelial activation and leukocyte effector...
7572409 - Leukotrienes and 15-lipoxygenase products in glomerulonephritis.
21197399 - Expression of proinflammatory and regulatory cytokines via nf-κb and mapk-dependent an...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology     Volume:  34     ISSN:  1537-4505     ISO Abbreviation:  Otol. Neurotol.     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-17     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100961504     Medline TA:  Otol Neurotol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  266-74     Citation Subset:  IM    
*Department of Otolaryngology Medical University of Bialystok, Bialystok, Poland; and †Department of Otorhinolaryngology, Head and Neck Surgery, Ruhr University Bochum, St. Elisabeth Hospital, Bochum, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Auditory and speech performance in deaf children with deaf parents after cochlear implant.
Next Document:  Engineering a BCR-ABL-activated caspase for the selective elimination of leukemic cells.